Combined Exposure Therapy and D-Cycloserine vs. Placebo for Posttraumatic Stress Disorder

This study provides a 12-14 week treatment for posttraumatic stress disorder related to the World Trade Center Attacks of September 11, 2001. Every patient will receive weekly individual therapy consisting of cognitive-behavioral treatment, including exposure therapy. In this treatment study, exposure will be enhanced by virtual reality and each patient will be randomly assigned to receive either D-Cycloserine or a placebo pill that is taken only on the day of the treatment when the exposure will be done for a total of 10-12 times. D-Cycloserine is a broad spectrum antibiotic that recently has been implicated as a cognitive enhancer which may speed up the learning process that occurs during exposure and/or make the gains more lasting.

New York Presbyterian Hospital/Weill Cornell Medical College
Principal Investigator: 
JoAnn Difede, PhD
Eligibility Criteria: 

Participants must be English-speaking adults with PTSD who witnessed the WTC attacks from nearby or farther and who are medically stable. Patients cannot participate if they have a serious comorbid mental illness, active suicidal or homicidal ideation, use a pacemaker, are pregnant or lactating, have a history of severe renal disease, seizures, or allergy to DCS, or are currently taking anticoagulants, ethionamide, or isoniazid.

Brittany Mello at The Program for Anxiety and Traumatic Stress Studies, 212-821-0783
New York, NY
New York

Contact ADAA

8701 Georgia Ave., Suite #412
Silver Spring, MD 20910


Contact ADAA

Request Publications



ADAA is a national nonprofit organization dedicated to the prevention, treatment, and cure of anxiety and mood disorders, OCD, and PTSD and to improving the lives of all people who suffer from them through education, practice, and research.


Privacy Policy 
© ADAA, 2010-2016